Private Equity 3 Days

Last updated: May 24, 2026, 5:30 PM ET

European Dealmaking Surge Closed a €5bn aerospace round highlighted the continued appetite for capital‑intensive sectors, while Frontenac prepared to sell its CV asset MCE underscored secondary‑market activity as Churchill Asset Management and 50 South Capital co‑led the transaction to extend Frontenac’s industrial exposure. The aerospace financing, led by a consortium of growth‑stage funds, pushed the weekly total of large‑scale deals past €10bn, a level not seen since early 2022, and signaled confidence in post‑pandemic demand for defense and commercial aircraft components. At the same time, Frontenac’s move reflects investors’ desire to recycle capital from mature industrial holdings into higher‑growth opportunities.

Healthcare‑Focused Private Equity Charterhouse, Iron Path and Revelar targeted pain‑management assets as part of a broader wave of investments that also included five pain‑management deals identified by PE firms. The sector’s attractiveness stems from an aging population and rising chronic‑pain prevalence, driving EBITDA multiples of 9‑12 × across recent transactions. Parallel to these add‑on buys, Charlesbank completed a merger of two med‑tech manufacturers into an orthopedics platform, creating a vertically integrated entity poised to capture synergies in product development and distribution. Collectively, the activity injected roughly $1.2bn of new equity into the niche, positioning private equity as a primary catalyst for consolidation in the pain‑care market.

Yield‑Oriented Strategies Expand Partners Group announced a total‑return strategy focused on mature heavy industries, citing a “white space” in corporate private equity for yield‑driven assets. The fund plans to allocate up to $2bn to sectors such as steel, chemicals and industrial equipment, where cash‑flow stability outweighs growth volatility. This shift aligns with CVC and GBL’s take‑private of Recordati, a deal that leverages predictable pharmaceutical cash flows to meet investor demand for lower‑beta exposure. Both moves illustrate a growing trend among global PE sponsors to balance high‑growth tech bets with traditional, cash‑generating businesses amid uncertain macro conditions.

Cross‑Border Consumer Health Acquisitions Avista and Damier agreed to acquire Belgium‑based vitamins producer Sanotact, adding a consumer‑health brand with €150m of annual revenue to a portfolio already anchored by nutraceuticals. The transaction, financed through a mix of debt and equity, reflects private equity’s increasing focus on health‑and‑wellness categories that exhibit resilient demand despite inflationary pressures. By integrating Sanotact’s product line with Damier’s existing distribution network, the owners anticipate cost synergies of up to 5% and an accelerated rollout into Southern European markets.

AI Startup Valuations Under Scrutiny Analysts warned that VCs and founders inflate ARR metrics for AI companies, a practice that can distort fundraising rounds and complicate exit timing for PE backers eyeing later‑stage buyouts. The report highlighted several “unicorn‑in‑the‑making” firms reporting ARR growth rates exceeding 300% YoY, yet lacking sustainable revenue streams. Private equity firms planning to enter the AI space are therefore tightening due diligence, focusing on cash‑conversion efficiency rather than headline growth, a shift that may temper the lofty valuations seen in recent venture rounds.